AbbVie Tops Q3 Expectations As Skyrizi, Rinvoq Drive Growth

On Wednesday, AbbVie Inc. (NYSE:ABBV) reported third-quarter adjusted EPS of $3.00, up from $2.95 a year ago, beating the consensus of $2.92.

Net revenues reached $14.46 billion, up 3.8%, beating the consensus of $14.28 billion. Sales were up 4.9% on an operational basis.

The immunology portfolio generated $7.05 billion in sales, up 3.9% on a reported basis or 4.8% on an operational basis.

Humira revenues were $2.23 billion (down 37.2%), Skyrizi sales reached $3.21 billion (up 50.8%), and Rinvoq revenues were $1.61 billion (up 45.3%). 

Also Read: FDA Approves AbbVie’s Parkinson’s Treatment, Medicare Coverage Expected Next Year

Oncology product sales were $1.69 billion, up 11.6% or 13.0% ...